SLC22A16 上调是胃癌的一个独立不良预后指标。
SLC22A16 upregulation is an independent unfavorable prognostic indicator in gastric cancer.
机构信息
Department of Clinical Laboratory Diagnosis, People's Hospital of Juxian, Rizhao, Shandong, 276500, PR China.
Clinical laboratory, Maternity & Child Health Care Hospital of Laizhou, Laizhou, 261499, PR China.
出版信息
Future Oncol. 2018 Sep;14(21):2139-2148. doi: 10.2217/fon-2018-0207. Epub 2018 Apr 26.
AIM
To study the expression profile of SLC22A16 in gastric cancer (GC), its prognostic value and the potential mechanisms of its upregulation.
PATIENTS & METHODS: A retrospective study was performed by using data in the Human Protein Atlas and The Cancer Genome Atlas-Stomach Cancer (STAD). Results: SLC22A16 was significantly upregulated in GC tissues compared with normal stomach tissues. SLC22A16 upregulation independently predicted poor overall survival (hazard ratio [HR]: 1.424, 95% CI: 1.169-1.735; p < 0.001) and recurrence-free survival (HR: 1.658, 95% CI: 1.292-2.128; p < 0.001) in early GC and poor overall survival (HR: 1.411, 95% CI: 1.137-1.752; p = 0.002) in advanced GC. SLC22A16 DNA hypomethylation might be a compensation for DNA loss to maintain SLC22A16 elevation in GC.
CONCLUSION
SLC22A16 might be a valuable prognostic marker in GC.
目的
研究 SLC22A16 在胃癌（GC）中的表达谱、其预后价值及其上调的潜在机制。
患者与方法
本研究采用了人类蛋白质图谱和癌症基因组图谱-胃癌（STAD）的数据进行回顾性研究。结果：与正常胃组织相比，SLC22A16 在 GC 组织中明显上调。SLC22A16 的上调独立预测早期 GC 的总生存期（HR：1.424，95%CI：1.169-1.735；p<0.001）和无复发生存期（HR：1.658，95%CI：1.292-2.128；p<0.001）不良，晚期 GC 的总生存期不良（HR：1.411，95%CI：1.137-1.752；p=0.002）。SLC22A16 的 DNA 低甲基化可能是一种补偿性机制，以维持 GC 中 SLC22A16 的升高，以弥补 DNA 的丢失。
结论
SLC22A16 可能是 GC 中一个有价值的预后标志物。
Zotero 插件